Orion Biotechnology acquires patent portfolio for potent CCR5 chemokine antagonist

OTTAWA, Sept. 06, 2018 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its subsidiary, Orion Biotechnology Switzerland Sàrl, has successfully closed a transaction with the Mintaka Medical Research Foundation for the acquisition of the 5P12-RANTES molecule. 5P12-RANTES is a potent CCR5 chemokine antagonist which Orion will develop … Read moreOrion Biotechnology acquires patent portfolio for potent CCR5 chemokine antagonist

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com